Intestinal Research

IBD
An integrative review of physical activity in adults with inflammatory bowel disease: Suja P Davis, Patricia B. Crane, Linda P. Bolin, Lee Ann Johnson; Intest Res. 2022;20(1):43-52. Published online January 22, 2021; DOI: https://doi.org/10.5217/ir.2020.00049
Web of Science 8 Crossref 10; Full text PubReader ePub PDF Supplementary Material

Microbiota
The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment: Sang Hoon Kim, Yun Jeong Lim; Intest Res. 2022;20(1):31-42. Published online May 21, 2021; DOI: https://doi.org/10.5217/ir.2021.00034
Web of Science 24 Crossref 22; Full text PubReader ePub PDF

IBD
Use of thiopurines in inflammatory bowel disease: an update: Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Rakesh Kochhar, Rupa Banerjee, Saroj Kant Sinha, Siew Chien Ng, Stephen Hanauer, Suhang Verma, Usha Dutta, Vandana Midha, Varun Mehta, Vineet Ahuja, Ajit Sood; Intest Res. 2022;20(1):11-30. Published online April 15, 2021; DOI: https://doi.org/10.5217/ir.2020.00155
Web of Science 37 Crossref 41; Full text PubReader ePub PDF

Management of inflammatory bowel disease in the COVID-19 era: Kyeong Ok Kim, Byung Ik Jang; Intest Res. 2022;20(1):3-10. Published online February 3, 2021; DOI: https://doi.org/10.5217/ir.2020.00156
Web of Science 15 Crossref 17; Full text PubReader ePub PDF

Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?: Jihye Park; Intest Res. 2022;20(1):1-2. Published online January 26, 2022; DOI: https://doi.org/10.5217/ir.2021.00170
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Miscellaneous
An elderly woman with severe enteritis mimicking infectious enteritis: Kazunori Nagashima, Takashi Kato, Taichi Kimura, Kazuma Kishi, Urara Baba; Intest Res. 2021;19(4):482-484. Published online July 3, 2020; DOI: https://doi.org/10.5217/ir.2020.00038; Full text PubReader ePub PDF

IBD
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model: Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon; Intest Res. 2021;19(4):478-481. Published online October 26, 2021; DOI: https://doi.org/10.5217/ir.2021.00121
Web of Science 3 Crossref 3; Full text PubReader ePub PDF

Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature: Eun Sil Kim, Ji Hyung Park, Yon Ho Choe, Mi Jin Kim; Intest Res. 2021;19(4):472-477. Published online October 29, 2020; DOI: https://doi.org/10.5217/ir.2020.00072
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Miscellaneous
Hydroxyurea associated ileocecal valve ulcer: evidence for causality: Thevaraajan Jayaraman, Ruveena Bhavani Rajaram, Gin Gin Gan, Ida Hilmi; Intest Res. 2021;19(4):468-471. Published online December 1, 2020; DOI: https://doi.org/10.5217/ir.2020.00099
Web of Science 1 Crossref 1; Full text PubReader ePub PDF

Inflammatory Bowel Diseases
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?: Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis; Intest Res. 2021;19(4):461-467. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00042
Web of Science 6 Crossref 5; Full text PubReader ePub PDF

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis: Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):448-460. Published online August 18, 2020; DOI: https://doi.org/10.5217/ir.2020.00026
Web of Science 9 Crossref 10; Full text PubReader ePub PDF Supplementary Material

High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis: Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja; Intest Res. 2021;19(4):438-447. Published online November 6, 2020; DOI: https://doi.org/10.5217/ir.2020.00055
Web of Science 7 Crossref 9; Full text PubReader ePub PDF Supplementary Material

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy: Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama; Intest Res. 2021;19(4):430-437. Published online November 9, 2020; DOI: https://doi.org/10.5217/ir.2020.00067
Web of Science 4 Crossref 5; Full text PubReader ePub PDF

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study: Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi; Intest Res. 2021;19(4):419-429. Published online November 10, 2020; DOI: https://doi.org/10.5217/ir.2020.00033
Web of Science 12 Crossref 13; Full text PubReader ePub PDF

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study: Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi; Intest Res. 2021;19(4):408-418. Published online November 20, 2020; DOI: https://doi.org/10.5217/ir.2020.00025
Web of Science 17 Crossref 13; Full text PubReader ePub PDF

Article category